anti anxiety agents

Summary

Summary: Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anesthesia adjuvants. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Top Publications

  1. ncbi The neurobiology and control of anxious states
    Mark J Millan
    Psychopharmacology Department, Centre de Rescherches de Croissy, Institut de Recherches IDR Servier, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France
    Prog Neurobiol 70:83-244. 2003
  2. ncbi The mouse light/dark box test
    Michel Bourin
    Faculty of Medicine, EA 3256 Neurobiologie de l Anxiété et de la Dépression, Faculté de Médecine BP 53508, 44035 Nantes cedex 1, France
    Eur J Pharmacol 463:55-65. 2003
  3. ncbi TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates
    John R Atack
    Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    J Pharmacol Exp Ther 316:410-22. 2006
  4. pmc Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates
    James K Rowlett
    Harvard Medical School, New England Primate Research Center, One Pine Hill Road, Box 9102, Southborough, MA 01772, USA
    Proc Natl Acad Sci U S A 102:915-20. 2005
  5. ncbi Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines
    Rebecca Dias
    The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex CM20 2QR, United Kingdom
    J Neurosci 25:10682-8. 2005
  6. ncbi Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol
    Fernando Berrendero
    Laboratori de Neurofarmacologia, Facultat de Ciencies de la Salut i de la Vida, Universitat Pompeu Fabra, c Doctor Aiguader 80, 08003 Barcelona, Spain
    Psychopharmacology (Berl) 163:111-7. 2002
  7. ncbi Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety
    N McNaughton
    Department of Psychology and Centre for Neuroscience, University of Otago, P O Box 56, Dunedin, New Zealand
    J Affect Disord 61:161-76. 2000
  8. ncbi Generalised anxiety disorder
    Peter Tyrer
    Department of Psychological Medicine, Division of Neuroscience and Mental Health, Imperial College, London W6 8RP, UK
    Lancet 368:2156-66. 2006
  9. pmc Models and mechanisms of anxiety: evidence from startle studies
    Christian Grillon
    Unit of Affective Psychophysiology, Mood and Anxiety Disorder Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 2670, USA
    Psychopharmacology (Berl) 199:421-37. 2008
  10. ncbi The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse
    J Adriaan Bouwknecht
    Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Neurosci Biobehav Rev 31:41-59. 2007

Detail Information

Publications247 found, 100 shown here

  1. ncbi The neurobiology and control of anxious states
    Mark J Millan
    Psychopharmacology Department, Centre de Rescherches de Croissy, Institut de Recherches IDR Servier, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France
    Prog Neurobiol 70:83-244. 2003
    ....
  2. ncbi The mouse light/dark box test
    Michel Bourin
    Faculty of Medicine, EA 3256 Neurobiologie de l Anxiété et de la Dépression, Faculté de Médecine BP 53508, 44035 Nantes cedex 1, France
    Eur J Pharmacol 463:55-65. 2003
    ..g. serotonergic drugs or drugs acting on neuropeptide receptors) can be detected using this paradigm. It has the advantages of being quick and easy to use, without requiring the prior training of animals...
  3. ncbi TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates
    John R Atack
    Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    J Pharmacol Exp Ther 316:410-22. 2006
    ..In summary, the novel alpha2/alpha3-selective efficacy profile of TPA023 translates into a nonsedating anxiolytic profile that is distinct from nonselective agonists...
  4. pmc Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates
    James K Rowlett
    Harvard Medical School, New England Primate Research Center, One Pine Hill Road, Box 9102, Southborough, MA 01772, USA
    Proc Natl Acad Sci U S A 102:915-20. 2005
    ..In contrast, stimulation of alpha1GABAA receptors is sufficient, but not necessary, for mediation of the abuse potential of these drugs...
  5. ncbi Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines
    Rebecca Dias
    The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex CM20 2QR, United Kingdom
    J Neurosci 25:10682-8. 2005
    ..Together, these data show that potentiation of alpha3-containing GABA(A) receptors is sufficient to produce the anxiolytic effects of BZs and that alpha2 potentiation may not be necessary...
  6. ncbi Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol
    Fernando Berrendero
    Laboratori de Neurofarmacologia, Facultat de Ciencies de la Salut i de la Vida, Universitat Pompeu Fabra, c Doctor Aiguader 80, 08003 Barcelona, Spain
    Psychopharmacology (Berl) 163:111-7. 2002
    ..Recent studies have shown that several pharmacological actions induced by cannabinoids, including antinociception and reward, involve the participation of the endogenous opioid system...
  7. ncbi Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety
    N McNaughton
    Department of Psychology and Centre for Neuroscience, University of Otago, P O Box 56, Dunedin, New Zealand
    J Affect Disord 61:161-76. 2000
    ..This pattern of results implies that there are many different types of arousal, only some of which appear to contribute to the generation of anxiety in normal subjects and to the etiology of pathological anxiety...
  8. ncbi Generalised anxiety disorder
    Peter Tyrer
    Department of Psychological Medicine, Division of Neuroscience and Mental Health, Imperial College, London W6 8RP, UK
    Lancet 368:2156-66. 2006
    ....
  9. pmc Models and mechanisms of anxiety: evidence from startle studies
    Christian Grillon
    Unit of Affective Psychophysiology, Mood and Anxiety Disorder Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 2670, USA
    Psychopharmacology (Berl) 199:421-37. 2008
    ....
  10. ncbi The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse
    J Adriaan Bouwknecht
    Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Neurosci Biobehav Rev 31:41-59. 2007
    ..The advantages and disadvantages of the SIH procedure as a physiological model of anxiety are discussed...
  11. ncbi Cognitive dysfunction resulting from hippocampal hyperactivity--a possible cause of anxiety disorder?
    N McNaughton
    Department of Psychology, University of Otago, Dunedin, New Zealand
    Pharmacol Biochem Behav 56:603-11. 1997
    ....
  12. ncbi Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype
    R M McKernan
    Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK
    Nat Neurosci 3:587-92. 2000
    ..This finding suggests ways to improve anxiolytics and to develop drugs for other neurological disorders based on their specificity for GABA(A) receptor subtypes in distinct neuronal circuits...
  13. pmc Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects
    Wen Jiang
    Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Clin Invest 115:3104-16. 2005
    ....
  14. ncbi Anxiolytic-like effect of paeonol in mice
    Xiao Juan Mi
    Department of Pharmacology, Shenyang Pharmaceutical University, Box 41, 103 Wenhua Road, 110016 Shenyang, P R China
    Pharmacol Biochem Behav 81:683-7. 2005
    ..5 mg/kg). Since paeonol, in contrast to diazepam, had no effect on either the number of squares entered in the open-field test or in the inclined plane test, its side-effect profile is considered as superior to the benzodiazepine...
  15. pmc Physician office visits of adults for anxiety disorders in the United States, 1985-1998
    Jeffrey S Harman
    Intervention Research Centers for Mid and Late Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
    J Gen Intern Med 17:165-72. 2002
    ..To determine the number of physician office visits by adults in which an anxiety disorder diagnosis was recorded and rates of treatment during these visits...
  16. ncbi Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling
    Sachin Patel
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    J Pharmacol Exp Ther 318:304-11. 2006
    ..These results suggest that pharmacological modulation of this system could represent a new approach to the treatment of anxiety-related psychiatric disorders...
  17. ncbi Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm
    H V Morris
    Department of Psychology, University of Sussex, Falmer, Brighton, BN1 9QG, UK
    Eur J Neurosci 23:2495-504. 2006
    ....
  18. ncbi Overview of diagnosis and drug treatments of anxiety disorders
    David J Nutt
    Psychopharmacology Unit, University of Bristol, Bristol, UK
    CNS Spectr 10:49-56. 2005
    ....
  19. ncbi Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt
    Miroslav M Savić
    Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia and Montenegro
    Pharmacol Biochem Behav 79:279-90. 2004
    ..On the other hand, the relative significance of the alpha(1)-subunit in the anxiogenic effects of DMCM could not be clearly deduced...
  20. pmc Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator
    A Lippa
    DOV Pharmaceutical, Inc, 433 Hackensack Avenue, Hackensack, NJ 07601, USA
    Proc Natl Acad Sci U S A 102:7380-5. 2005
    ..g., sedation, dizziness) in ocinaplon-treated patients did not differ from placebo. These findings indicate that ocinaplon represents a unique approach both for the treatment and understanding of anxiety disorders...
  21. ncbi Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
    Agnieszka Palucha
    Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31 343 Krakow, Poland
    Pharmacol Ther 115:116-47. 2007
    ..However, preclinical data also indicates that ligands of these receptors, both agonists and antagonists, may have an anxiolytic-like and antidepressant-like potential...
  22. ncbi Functional impact and health utility of anxiety disorders in primary care outpatients
    Murray B Stein
    Department of Psychiatry, University of California San Diego, La Jolla, CA 92093 0985, USA
    Med Care 43:1164-70. 2005
    ..The objective of this study was to examine the relative impact of anxiety disorders and major depression on functional status and health-related quality of life of primary care outpatients...
  23. ncbi Molecular and neuronal substrate for the selective attenuation of anxiety
    K Low
    Institute of Pharmacology and Toxicology, University of Zurich, and Swiss Federal Institute of Technology Zürich ETH, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Science 290:131-4. 2000
    ....
  24. ncbi Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats
    Ewa Tatarczyńska
    Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 3 1 343 Kraków, Poland
    Pol J Pharmacol 54:707-10. 2002
    ..These data suggest that selective group III mGlu receptor agonists may become a new class of anxiolytics and/or antidepressants...
  25. ncbi Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine
    E E Irvine
    Neuroscience Research Centre, GKT School of Biomedical Sciences, King s College London, UK
    Behav Pharmacol 10:691-7. 1999
    ..Thus, an oppositional mechanism may underlie tolerance to the anxiolytic effects, whereas there is as yet no evidence for this type of mechanism mediating tolerance to the anxiogenic effects...
  26. ncbi Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
    S L de Haas
    Centre for Human Drug Research, Leiden, The Netherlands
    J Psychopharmacol 21:374-83. 2007
    ..Contrary to lorazepam, TPA023 caused no detectable memory impairment or postural imbalance. These differences reflect the selectivity of TPA023 for different GABA(A) receptor subtypes...
  27. pmc Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress
    Christiaan H Vinkers
    Department of Psychopharmacology, Utrecht Institute for Pharmaceutical Sciences and Rudolf Magnus Institute of Neuroscience, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    Psychopharmacology (Berl) 204:299-311. 2009
    ..The GABA(A) receptor alpha(1) subunit is associated with sedation, whereas the GABA(A) receptor alpha(2) and alpha(3) subunits are involved in anxiolytic effects...
  28. ncbi Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test
    Sabrina F Lisboa
    Department of Pharmacology, School of Medicine of Ribeirao Preto, USP, Av Bandeirantes 3900, Ribeirao Preto, Sao Paulo, Brazil
    Eur J Pharmacol 593:73-8. 2008
    ..These effects were prevented by AM251. The results give further support to the proposal that facilitation of CB(1) receptor-mediated endocannabinoid neurotransmission in the dorsolateral periaqueductal gray modulates defensive responses...
  29. ncbi Stress-induced hyperthermia and anxiety: pharmacological validation
    Berend Olivier
    Department of Psychopharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, The Netherlands
    Eur J Pharmacol 463:117-32. 2003
    ....
  30. pmc Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission
    J Haller
    Institute of Experimental Medicine, Department of Behavioral Neurobiology, 1450 Budapest, PO Box 67, Hungary
    Eur J Neurosci 25:2445-56. 2007
    ..We suggest that the anxiety-related effects of cannabinoids depend on the relative cannabinoid responsiveness of GABAergic and glutamatergic neurotransmission...
  31. ncbi Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology
    Christian Grillon
    National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 52:958-75. 2002
    ..Lacking a cue for threat, the organism cannot identify periods of danger and safety and remains in a chronic state of anxiety. Factors that may affect conditioning are discussed...
  32. ncbi 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze
    R J Rodgers
    Behavioural Pharmacology Laboratory, School of Psychology, University of Leeds, Leeds LS2 9JT, UK
    Eur J Neurosci 17:1279-86. 2003
    ..Data are discussed in relation to the recently described phenotypes of CB1 receptor knockout mice and, in particular, to mounting evidence for the existence of a novel SR141716A-sensitive neuronal cannabinoid receptor...
  33. ncbi Treatment adequacy of anxiety and depressive disorders: primary versus specialised care in Spain
    Anna Fernandez
    Sant Joan de Deu SSM, Fundació Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
    J Affect Disord 96:9-20. 2006
    ..This study aimed to describe the adequacy of treatment for Anxiety and Depressive disorders in Spain, how this differs between providers (primary versus specialised care) and which factors are associated with appropriate care...
  34. ncbi A review of 25 years of the social interaction test
    Sandra E File
    Psychopharmacology Research Unit, Centre for Neuroscience, King s College London, Guy s Campus, UK
    Eur J Pharmacol 463:35-53. 2003
    ..The use of this test has, thus, played a crucial role in unravelling the neural basis of anxiety. It is hoped that in the next 25 years, the test will play a crucial role in determining the genetic basis of anxiety disorders...
  35. ncbi The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle
    Christian Grillon
    Mood and Anxiety Disorder Program, National Institutes of Mental Health, Bethesda, Maryland 20892 2670, USA
    Biol Psychiatry 60:760-6. 2006
    ..The present study tested the hypothesis that alprazolam would reduce the sustained startle potentiation to contextual threats but not the startle potentiation to a threat cue...
  36. ncbi Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats
    Małgorzata Pietraszek
    Preclinical R and D, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt am Main, Germany
    Eur J Pharmacol 514:25-34. 2005
    ....
  37. ncbi Patterns and correlates of benzodiazepine use in the French general population
    Rajaa Lagnaoui
    Departement de Pharmacologie, EA 3676, IFR 99, Universite Victor Segalen, Bordeaux 2, 33076 Bordeaux, France
    Eur J Clin Pharmacol 60:523-9. 2004
    ..To investigate the prevalence of current use of benzodiazepines (BZDs) and related drugs in the French general population and factors associated with this use...
  38. ncbi Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
    Guy Griebel
    Sanofi Aventis Recherche, Bagneux, France
    Biol Psychiatry 57:261-7. 2005
    ..The endocannabinoid system has been implicated in the modulation of emotional processes...
  39. ncbi Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes
    U Rudolph
    Institute of Pharmacology, University of Zurich, Switzerland
    Nature 401:796-800. 1999
    ..Thus, benzodiazepine-induced behavioural responses are mediated by specific GABA(A) receptor subtypes in distinct neuronal circuits, which is of interest for drug design...
  40. ncbi Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety
    Mariusz Papp
    Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    Behav Pharmacol 17:9-18. 2006
    ..These results indicate the involvement of both the melatonin and the 5-HT2C receptors in the mechanism of anxiolytic-like action of agomelatine...
  41. ncbi In adolescence, female rats are more sensitive to the anxiolytic effect of nicotine than are male rats
    S Cheeta
    Psychopharmacology Research Unit, Centre for Neuroscience, GKT School of Biomedical Sciences, King's College London, Hodgkin Building, Guy's Campus, SE1 1UL, London, UK
    Neuropsychopharmacology 25:601-7. 2001
    ..This sex difference in sensitivity to nicotine's anxiolytic effects suggests there may be sex differences in the factors initiating and maintaining teenage smoking...
  42. ncbi Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
    Fabricio A Moreira
    Department of Pharmacology, FMRP, University of Sao Paulo, Av Bandeirantes, 3900, 14049 900, Ribeirao Preto, SP, Brazil
    Prog Neuropsychopharmacol Biol Psychiatry 30:1466-71. 2006
    ..These results reinforce the hypothesis that this cannabinoid has anxiolytic properties...
  43. ncbi Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
    Alline Cristina Campos
    Department of Pharmacology, School of Medicine of Ribeirao Preto, Campus USP, Av Bandeirantes 3900, Monte Alegre, Ribeirao Preto, SP, Brazil
    Psychopharmacology (Berl) 199:223-30. 2008
    ..In addition, since CBD has been shown to inhibit anandamide metabolism, CB1 receptors could also be involved in the effects of this cannabinoid...
  44. ncbi The role of pharmacogenetics in the treatment of depression and anxiety disorders
    Alexandra Schosser
    Department of Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Vienna, Austria
    Int Clin Psychopharmacol 24:277-88. 2009
    ..The current review not only updates pharmacogenetic research in depression but also focuses on antidepressant treatment response in anxiety disorders...
  45. ncbi Three decades of antidepressant, anxiolytic and hypnotic use in a national population birth cohort
    Ian Colman
    Department of Psychiatry, University of Cambridge, UK
    Br J Psychiatry 189:156-60. 2006
    ..Psychotropic medication use is common and increasing. Use of such drugs at the individual level over long periods has not been reported...
  46. ncbi A detailed ethological analysis of the mouse open field test: effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field
    E Choleris
    Room 9222D, Department of Psychology, Social Science Center, University of Western Ontario, London, Ontario, Canada N6A 5C2
    Neurosci Biobehav Rev 25:235-60. 2001
    ..e. pulsed magnetic field) on anxiety-like behaviors, but also permits the examination of non-specific effects, in particular those on general activity...
  47. pmc Treating generalised anxiety disorder
    Alison Tonks
    BMJ Unified, London WC1H 9JR
    BMJ 326:700-2. 2003
  48. ncbi Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats
    A Pałucha
    Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31 343, Krakow, Poland
    Neuropharmacology 46:151-9. 2004
    ..In conclusion, the results of our studies indicate that group III mGlu receptor agonists may play a role in the therapy of both anxiety and depression...
  49. ncbi Anxiolytic-like properties of the anandamide transport inhibitor AM404
    Marco Bortolato
    Department of Psychiatry and Human Behavior, Center for Drug Discovery, University of California, Irvine, CA 92697 4625, USA
    Neuropsychopharmacology 31:2652-9. 2006
    ..These results support a role of anandamide in the regulation of emotion and point to the anandamide transport system as a potential target for anxiolytic drugs...
  50. ncbi Effects of rolipram on the elevated plus-maze test in rats: a preliminary study
    J S Silvestre
    Department of Pharmacology, Research Centre, Almirall Prodesfarma, Barcelona, Spain
    J Psychopharmacol 13:274-7. 1999
    ....
  51. ncbi Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors
    Leyre Urigüen
    Servicio de Psiquiatría y Unidad de Investigación, Pabellon de Medicina Comunitaria, Hospital Universitario 12 de Octubre, Avda Cordoba s n, 28041 Madrid, Spain
    Neuropharmacology 46:966-73. 2004
    ..They suggest that alterations in the functional activity of the CB(1) receptor may be related to the emergence of anxiety disorders, and may affect treatment with anxiolytics...
  52. ncbi Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety
    David L Walker
    Department of Psychiatry and Behavioral Sciences and The Center for Behavioral Neuroscience, Emory University School of Medicine, 1639 Pierce Dr, Atlanta, GA 30322, USA
    Psychopharmacology (Berl) 164:318-28. 2002
    ..However, when the tested compounds also influence baseline startle, it is unclear how comparisons with control groups can best be made...
  53. ncbi CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents
    J Haller
    Institute of Experimental Medicine, Budapest, Hungary
    Behav Pharmacol 15:299-304. 2004
    ..This suggests that agonists of the former, or antagonists of the latter, are promising new compounds in the pharmacotherapy of anxiety...
  54. ncbi Light-enhanced startle: further pharmacological and behavioral characterization
    David L Walker
    Department of Psychiatry and Behavioral Sciences and the Center for Behavioral Neurosciences, Emory University School of Medicine, Woodruff Memorial Building, Suite 4000, 1639 Pierce Drive, Atlanta, GA 30322, USA
    Psychopharmacology (Berl) 159:304-10. 2002
    ..To characterize this phenomenon further, we evaluate here the sensitivity of light-enhanced startle to the anxiolytic compound chlordiazepoxide, to the noradrenergic beta-receptor antagonist propranolol, and to pre-test handling...
  55. ncbi The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine
    Reinoud de Jongh
    Department of Psychopharmacology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    Psychopharmacology (Berl) 159:176-80. 2002
    ..By placing a rat in a brightly lit environment, which is a naturally aversive stimulus to rats, the amplitude of the startle response to a startle-eliciting noise burst is increased...
  56. ncbi Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine
    Lionel Waintraub
    Service de Psychiatrie du Pr J D Guelfi, Centre Hospitalier Paul Brousse, Villejuif, France
    CNS Drugs 16:65-75. 2002
    ..Zopiclone use was assessed to provide an indirect evaluation of the possible hypnotic activity of both treatments...
  57. ncbi Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats
    Leonardo B M Resstel
    Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP 14090 090, Brazil
    Behav Brain Res 172:294-8. 2006
    ..In conclusion, the results suggest that CBD has anxiolytic-like properties similar to those of diazepam in a rat model of conditioned fear to context...
  58. ncbi Benzodiazepines have no effect on fear-potentiated startle in humans
    Johanna M P Baas
    Mood and Anxiety Disorder Program, NIMH, NIH, 15k North Drive MSC 2670, Bethesda, MD 20892, USA
    Psychopharmacology (Berl) 161:233-47. 2002
    ..Pre-clinical and clinical investigations have provided a great deal of evidence that the fear-potentiated startle paradigm represents a valid model for the objective assessment of emotional states of anxiety and fear...
  59. ncbi Anxiolytic-like actions of leaves of Casimiroa edulis (Rutaceae) in male Wistar rats
    M Molina-Hernandez
    Laboratorio de Conducta, Instituto de Investigaciones Psicologicas, Universidad Veracruzana, P O Box 361, Jalapa, Veracruz, Mexico Zip 91000, Mexico
    J Ethnopharmacol 93:93-8. 2004
    ..In conclusion, the leaves of Casimiroa edulis (Rutaceae) produced anxiolytic-like actions in male Wistar rats, with several side actions, namely, reduced locomotion and neutralization of the antidepressant-like actions of desipramine...
  60. ncbi Tolerance in the anxiolytic profile following repeated administration of diazepam but not buspirone is associated with a decrease in the responsiveness of postsynaptic 5-HT-1A receptors
    Asma Khan
    Department of Biochemistry, Neurochemistry and Biochemical Neuropharmacology Research Unit, University of Karachi, Karachi 75270, Pakistan
    Acta Biol Hung 58:345-57. 2007
    ..Role of 5-HT-1A receptors in the development of tolerance to the anxiolytic effects of diazepam but not buspirone is discussed...
  61. ncbi Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study
    T A Furukawa
    Department of Psychiatry, Nagoya City University Medical School, Mizuho cho Mizuho ku, Nagoya 467 8601, Japan
    J Affect Disord 65:173-7. 2001
    ..However, benzodiazepines themselves have little or no antidepressive effects and we lack firm evidence for or against this combination therapy. We therefore conducted a meta-analysis of relevant randomized controlled trials to date...
  62. ncbi Pharmacotherapy for social anxiety disorder: a systematic review
    Jonathan C Ipser
    UCT Department of Psychiatry and Mental Health, Groote Schuur Hospital, J 2 Anzio Road, Observatory, 7925, South Africa
    Expert Rev Neurother 8:235-57. 2008
    ..Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and The Cochrane Library should be consulted for the most recent version of the review...
  63. ncbi Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans
    Christian Grillon
    NIMH NIH DHHS, Mood and Anxiety Disorder Program, 15K North Drive, MSC 2670, Bethesda, MD 20892 2670, USA
    Psychopharmacology (Berl) 168:446-54. 2003
    ..LY354740, a structural analogue of glutamate that shows specificity at the mGluR2/3 receptor, has anxiolytic effects in animal models...
  64. ncbi Attending to anxiety disorders in primary care
    Murray B Stein
    University of California, San Diego, La Jolla 92037, USA
    J Clin Psychiatry 64:35-9. 2003
    ..It is therefore important for primary care physicians to recognize and treat patients with anxiety disorders...
  65. ncbi Effects of cannabidiol (CBD) on regional cerebral blood flow
    José Alexandre de Souza Crippa
    Department of Neuropsychiatry and Medical Psychology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil
    Neuropsychopharmacology 29:417-26. 2004
    ..001). These results suggest that CBD has anxiolytic properties, and that these effects are mediated by an action on limbic and paralimbic brain areas...
  66. ncbi Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
    S L de Haas
    Centre for Human Drug Research, Leiden, The Netherlands
    J Psychopharmacol 22:24-32. 2008
    ..Clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile...
  67. ncbi Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
    A W Zuardi
    Departamento de Neurologia, Psiquiatria e Psicologia Medica, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brazil
    Braz J Med Biol Res 39:421-9. 2006
    ..Future studies of CBD in other psychotic conditions such as bipolar disorder and comparative studies of its antipsychotic effects with those produced by clozapine in schizophrenic patients are clearly indicated...
  68. ncbi The mouse light-dark paradigm: a review
    M Hascoet
    Faculty of Medicine, JE 2029 Neurobiologie de l anxiété, Faculty de Medecine, Nantes, France
    Prog Neuropsychopharmacol Biol Psychiatry 25:141-66. 2001
    ..g. serotonergic drugs) can be detected using this paradigm. It has the advantages of being quick and easy to use, without requiring the prior training of animals...
  69. ncbi Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study
    J Riba
    , Institut de Recerca, Hospital de la Santa Creu i Sant Pau, St. Antoni Maria Claret, 167, 08025 Barcelona, Spain
    Psychopharmacology (Berl) 157:358-67. 2001
    ....
  70. ncbi Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice
    Zul Merali
    Institute of Mental Health Research, Royal Ottawa Hospital, and Department of Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada
    Biol Psychiatry 54:552-65. 2003
    ....
  71. ncbi Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress
    Matthew N Hill
    Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, BC, Canada V6T 1Z4
    Eur J Pharmacol 499:291-5. 2004
    ..These findings suggest that chronic stress enhances either cannabinoid receptor responsivity or one of the interacting systems implicated in emotional states...
  72. ncbi Anxiolytic effects of flesinoxan in the stress-induced hyperthermia paradigm in singly-housed mice are 5-HT1A receptor mediated
    B Olivier
    CNS Pharmacology, Solvay Pharmaceuticals, Weesp, The Netherlands
    Eur J Pharmacol 342:177-82. 1998
    ..The stress-induced hyperthermia paradigm in singly-housed mice represents a simple and robust paradigm to measure putative anxiolytic effects of drugs...
  73. ncbi Evidence-based pharmacotherapy of Generalized Anxiety Disorder
    David S Baldwin
    Clinical Neurosciences Division, Faculty of Medicine, Health and Life Sciences, University of Southampton, UK
    Int J Neuropsychopharmacol 8:293-302. 2005
    ..The management of patients who do not respond to first-line treatment is uncertain, but some patients may benefit from certain tricyclic antidepressants, buspirone, or pregabalin...
  74. ncbi Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats
    M L Molchanov
    Department of Pharmacology, FMRP, Campus USP, 14049 900 Ribeirao Preto, SP, Brazil
    Psychopharmacology (Berl) 160:30-8. 2002
    ..Other columns of the PAG are also involved in defensive reactions. Few studies, however, have investigated the effects of pharmacological manipulation of the ventrolateral PAG (VLPAG) on procedures that predict anxiolytic activity...
  75. ncbi Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite
    H V Pai
    Department of Neurochemistry, National Institute of Mental Health and Neurosciences, Bangalore, India
    Pharmacogenomics J 2:243-58. 2002
    ..Since hydroxy metabolites of alprazolam are hydrophilic and not easily cleared through blood-CSF barrier, alpha-OHALP would potentially have a longer half-life in brain...
  76. ncbi The effects of angelica essential oil in three murine tests of anxiety
    Si Wei Chen
    Department of Pharmacology, Shenyang Pharmaceutical University, Box 41, 103 Wenhua Road, 110016 Shenyang, P R China
    Pharmacol Biochem Behav 79:377-82. 2004
    ..Further studies will be required to assess the generality of the present findings to other species and behavioural paradigms...
  77. ncbi Effectiveness of benzodiazepines: do they work or not?
    Malcolm Lader
    P056, Institute of Psychiatry, King s College, London, Denmark Hill, London, SE5 8AF, UK
    Expert Rev Neurother 8:1189-91. 2008
    ..I point out the changes in diagnostic criteria over the years and the lack of accepted methods of assessing estimates of effectiveness in clinical practice. Excessive prescribing of these controversial drugs is likely to continue...
  78. ncbi Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety
    Michael G N Russell
    J Med Chem 49:1235-8. 2006
    ..Compound 11 shows good bioavailability and half-life in preclinical species, and it is a nonsedating anxiolytic in both rat and squirrel monkey behavioral models...
  79. ncbi A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers
    Jayne E Bailey
    Psychopharmacology Unit, Department of Respiratory Medicine, University of Bristol, United Bristol Healthcare Trust, UK
    J Psychopharmacol 21:42-9. 2007
    ..In these studies we have shown that this CO2 model of anxiety is sensitive to lorazepam and to a lesser extent paroxetine. This gives support to its utility as an experimental model of general anxiety disorder in healthy volunteers...
  80. ncbi A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety
    J E Bailey
    Psychopharmacology Unit, University of Bristol, Bristol, UK
    J Psychopharmacol 23:117-22. 2009
    ....
  81. pmc Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains
    Motoo Yamauchi
    Department of Medicine, Case Western Reserve University, VA Medical Center, Research Service K216, 10701 East Blvd, Cleveland, OH 44106, USA
    J Appl Physiol (1985) 105:518-26. 2008
    ..We conclude that buspirone improves posthypoxic ventilatory irregularities in the B6 mouse through its agonist effects on the 5-HT1A receptor...
  82. ncbi Mechanism of action of alpha2delta ligands: voltage sensitive calcium channel (VSCC) modulators
    Stephen M Stahl
    Neuroscience Education Institute in Carlsbad, Calif, and the Department of Psychiatry at the University of California San Diego, 92009, USA
    J Clin Psychiatry 65:1033-4. 2004
    ..Modulation of VSCCs by certain drugs such as pregabalin and gabapentin via binding to the alpha2delta subunits of VSCCs can lead to anticonvulsant, anxiolytic, and chronic pain-relieving actions...
  83. pmc Correlates of nonmedical use of prescription benzodiazepine anxiolytics: results from a national survey of U.S. college students
    Sean Esteban McCabe
    University of Michigan, Substance Abuse Research Center, 2025 Traverwood Dr, Suite C, Ann Arbor, MI 48105 2194, USA
    Drug Alcohol Depend 79:53-62. 2005
    ....
  84. ncbi GABA-based therapeutic approaches: GABAA receptor subtype functions
    Uwe Rudolph
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland, and Laboratory of Genetic Neuropharmacology, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Curr Opin Pharmacol 6:18-23. 2006
    ..Thus, a new pharmacology based on GABAA receptor subtype-specific actions is emerging...
  85. ncbi mCPP-induced anxiety in the light-dark box in rats--a new method for screening anxiolytic activity
    A Bilkei-Gorzo
    EGIS Pharmaceuticals Ltd, Department of CNS Pharmacology, Budapest, Hungary
    Psychopharmacology (Berl) 136:291-8. 1998
    ..We conclude that mCPP-induced anxiety in the light-dark box is a potent and useful method for screening and detecting anxiolytic activity of a wide range of compounds with various modes of action...
  86. ncbi World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders
    Borwin Bandelow
    Department of Psychiatry and Psychotherapy, University of Gottingen, Germany
    World J Biol Psychiatry 3:171-99. 2002
    ..For social phobia, SSRIs are recommended for the first line, and MAOIs, moclobemide and benzodiazepines as second line. Obsessive-compulsive disorder is best treated with SSRIs or clomipramine...
  87. ncbi SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors
    G Griebel
    CNS Research Department, Discovery Research, Sanofi Synthelabo, Bagneux, France
    J Pharmacol Exp Ther 298:753-68. 2001
    ..The "anxioselective" profile of SL651498 points to a major role for GABA(A) alpha2 subtype in regulating anxiety and suggests that selectively targeting GABA(A) receptor subtypes can lead to drugs with increased clinical specificity...
  88. ncbi The dorsal raphé nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses
    S Cheeta
    Psychopharmacology Research Unit, Centre for Neuroscience, GKT School of Biomedical Sciences, King's College London, Hodgkin Building, Guy's Campus, London SE1 UL, UK
    Psychopharmacology (Berl) 155:78-85. 2001
    ....
  89. ncbi Pharmacology of human experimental anxiety
    F G Graeff
    Departamento de Neurologia, Psiquiatria e Psicologia Medica, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brasil
    Braz J Med Biol Res 36:421-32. 2003
    ..In spite of ethical and economic constraints, human experimental anxiety constitutes a valuable tool for the study of the pathophysiology of anxiety disorders...
  90. ncbi The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors
    Piotr Popik
    Behavioral Neuroscience, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    J Pharmacol Exp Ther 319:1244-52. 2006
    ....
  91. ncbi Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone
    Katsuya Harada
    Pharmacology Research Laboratories, Astellas Pharma Inc, 21 Miyukigaoka, Tsukuba, Ibaraki 305 8585, Japan
    Eur J Pharmacol 553:171-84. 2006
    ....
  92. ncbi Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam
    Eva Fries
    Daacro Clinical Research Organization, Novalisstrasse 12 a, 54295 Trier, Germany
    Psychoneuroendocrinology 31:1278-88. 2006
    ..In healthy subjects, we observed a dissociation of the effects of alprazolam on the endocrine and the autonomic response to psychosocial stress. The psychological responses seemed to be masked by sedative properties of alprazolam...
  93. ncbi Involvement of presynaptic 5-HT(1A) and benzodiazepine receptors in the anticonflict activity of 5-HT(1A) receptor antagonists
    Anna Wesołowska
    Institute of Pharmacology, Polish Academy of Sciences, 31 343 Cracow, Poland
    Eur J Pharmacol 471:27-34. 2003
    ....
  94. ncbi TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice
    Richard Young
    Department of Medicinal Chemistry, School of Pharmacy, Box 980540, Virginia Commonwealth University, 410 North 12th Street, Richmond, VA 23298 0540, USA
    Pharmacol Biochem Behav 84:62-73. 2006
    ..Moreover, the IV administration of TDIQ, up to 10 mg/kg, produced negligible effects on the HR and BP of mice. TDIQ could be a lead candidate for a new type of structural compound in the treatment of certain forms of anxiety...
  95. ncbi Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test
    Oliver Grundmann
    College of Pharmacy, Department of Pharmaceutics, University of Florida, Gainesvilla, FL 32610, USA
    J Ethnopharmacol 110:406-11. 2007
    ..These results indicate that AV extract is an effective anxiolytic agent, and suggest that the anxiolytic-like activities of this plant are mainly mediated via the GABAergic system...
  96. ncbi Quality of life in social anxiety disorder compared with panic disorder and the general population
    Naomi M Simon
    Anxiety Disorders Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Psychiatr Serv 53:714-8. 2002
    ..Quality of life in a treatment-seeking cohort of patients with social anxiety disorder was compared with that of patients with panic disorder who were matched for age, comorbid illnesses, and gender and with population-based norms...
  97. ncbi The effect of neonatal handling on adult feeding behavior is not an anxiety-like behavior
    P P Silveira
    Department of Biochemistry, ICBS, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil
    Int J Dev Neurosci 23:93-9. 2005
    ....
  98. ncbi Anxiolytic-like effects of ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng
    Jeong Hill Park
    College of Pharmacy, Seoul National University, Seoul, 151 742, S Korea
    Prog Neuropsychopharmacol Biol Psychiatry 29:895-900. 2005
    ..Ginseng saponins have been suggested to play an important role in the anxiolytic effects of ginseng. We provide evidence that ginseng may be useful for the treatment of anxiety...
  99. ncbi Ethological comparison of the effects of a bovine alpha s1-casein tryptic hydrolysate and diazepam on the behaviour of rats in two models of anxiety
    Nicolas Violle
    Neurosciences Comportementales, URAFPA, INRA UC12340, INPL UHP, 54500 Vandoeuvre les Nancy, France
    Pharmacol Biochem Behav 84:517-23. 2006
    ..These results suggest that the mechanism of action of the bovine alpha s1-casein tryptic hydrolysate may differ from that of diazepam...
  100. ncbi Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders
    Sarah K Leonard
    Depression and Anxiety Disorders, Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 197:601-11. 2008
    ..Neuropeptide S (NPS) and its receptor (NPSR) comprise a recently deorphaned G protein-coupled receptor system. Recent reports implicate NPS in the mediation of anxiolytic-like activity in rodents...
  101. ncbi Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression
    Anna Wesołowska
    Department of New Drugs Research, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31 343 Krakow, Poland
    Neuropharmacology 52:1274-83. 2007
    ..Such data indicate that the selective 5-HT(6) receptor antagonist SB-399885had specific effects, indicative of this compound's anxiolytic and antidepressant potential...

Research Grants62

  1. Design and Synthesis of Anxioselective Anxiolytics
    James M Cook; Fiscal Year: 2010
    ..This latter research may also have implications in Alzheimer's disease and schizophrenia. ..
  2. PTSD Hyperarousal Symptoms Treated with Physiological Stress Management
    WALTON THOMPSON ROTH; Fiscal Year: 2011
    ..Physiological monitoring will be applied not only during the training exercises and in the laboratory, but also ambulatorily for 24-hour periods that include daily activities and sleep. ..
  3. Design of a high-throughput screen for chemicals that cause meiotic aneuploidy
    Patrick Allard; Fiscal Year: 2011
    ....
  4. Structural Rearrangements in GABA-A Receptors
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2012
    ....
  5. Neurosteroid-BZ combinations: Strategy for reducing abuse and sedation
    James K Rowlett; Fiscal Year: 2013
    ..The ultimate goal for this research program is to provide critical preclinical information for development of a broadly effective combination product with an improved side effect profile for treating anxiety disorders. ..
  6. Design of a high-throughput screen for chemicals that cause meiotic aneuploidy
    Patrick Allard; Fiscal Year: 2013
    ..Together, we will be able, for the first time, to assess the meiotic aneugenic activity of our environment and improve our ability to predict toxicity to mammals and humans. ..
  7. Structure of the GABA-A Receptor Binding Sites
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2013
    ....
  8. Structure of the GABA-A Receptor Binding Sites
    CYNTHIA M CZAJKOWSKI; Fiscal Year: 2012
    ..abstract_text> ..
  9. Use of a mouse model of anxious depression to assess the safety of pediatric anti
    Bernhard Luscher; Fiscal Year: 2010
    ..In addition, they may advance the design and safety of antidepressant and anxiolytic therapies directed specifically at pediatric and adolescent patients. ..
  10. Cellular Pharmacology of Kappa Opiod Receptor
    Lee Yuan Liu-Chen; Fiscal Year: 2013
    ..In addition, such understanding will have important implications for other membrane bound receptors since these regulatory mechanisms of export are likely to be applicable to some other proteins. ..
  11. Role of Gi/o-Protein Inhibition of CaV2.2 Channels in Anxiety Behavior
    Arturo Andrade; Fiscal Year: 2013
    ..Using mouse models of tolerance, I will measure the sensitivity CaV2.2 channels to Gi/oPCR inhibition mediated by exogenous agonists in na[unreadable]ve and drug-treated mice in glutamatergic transmission. ..
  12. Emory-MSSM-GSK-NIMH Collaborative Mood and Anxiety Disorders Initiative
    Helen S Mayberg; Fiscal Year: 2013
    ..abstract_text> ..
  13. Change in Opioid use and overdose after a medicaid lock-in program
    Asheley C Skinner; Fiscal Year: 2013
    ..The results of this study have the potential to substantially reduce the cost of CS abuse in terms of human lives and financial resources. ..
  14. ANXIOLYTIC EFFECTS AND ABUSE OF BZ RECEPTOR LIGANDS
    James K Rowlett; Fiscal Year: 2013
    ..abstract_text> ..
  15. MVPS: Health Concerns, Role function, Health Service Use
    KRISTINE SCORDO; Fiscal Year: 2002
    ....
  16. Preclinical Evaluation of Medications to Treat Polydrug Addiction
    Jack Bergman; Fiscal Year: 2013
    ..These multi-disciplinary studies will facilitate translation of novel polydrug abuse medications into clinical treatment. ..
  17. BETA-CARBOLINES: VALIUM AGONISTS AND ANTAGONISTS
    James Cook; Fiscal Year: 1992
    ....
  18. RECEPTOR POPULATIONS UNDERLYING TONIC GABA CURRENTS IN HIPPOCAMPUS
    Steven J Mennerick; Fiscal Year: 2013
    ..Aim 2 will test the physiological implications for excitability and for positive allosteric modulation of tonic current mediated by high affinity extrasynaptic receptors versus low-affinity synaptic receptors. ..
  19. EMOTIONAL CONTROL OF SEDATIVE SELF-MEDICATION IN PTSD
    JOHN CASADA; Fiscal Year: 2003
    ..More importantly, the data also will provide practical information for the clinical treatment of PTSD patients and others with anxiety who may be at risk for abusing prescription anxiolytics or alcohol. ..
  20. Endogenous GABAergic Activity
    Istvan Mody; Fiscal Year: 2007
    ....
  21. BIOSYNTHESIS OF OLEAMIDE AND OTHER FATTY ACID AMIDES
    DAVID MERKLER; Fiscal Year: 1999
    ..Accomplishing this goal will establish the role of a-AE and oleoylglycine in the biosynthesis oleamide in the mammalian cells of neural origin. ..
  22. STIMULUS PROPERTIES OF ANXIOLYTICS IN HUMANS
    Chris Ellyn Johanson; Fiscal Year: 1991
    ....
  23. Non-sedating modulators of GABA-A receptors for anxiety
    KELVIN GEE; Fiscal Year: 2009
    ..The focus of the proposed project is to develop therapeutics to bolster the shortfall of therapies for the treatment of anxiety disorders, an underserved therapeutic area that affects 3.1% of the general population over 18. ..
  24. PERIOPERATIVE PAIN, IMMUNE FUNCTION, AND METASTASIS
    Gayle Page; Fiscal Year: 2001
    ....
  25. Melatonin Analog PD6735 and Anxiety
    Frank Zemlan; Fiscal Year: 2006
    ..Further, measure plasma and brain PD6735 levels immediately after behavioral testing and determine the relationship between anxiety measures and plasma/brain PD6735 levels. [unreadable] [unreadable] [unreadable]..
  26. BENZODIAZEPINES--TOLERANCE AND ACUTE/CHRONIC DEPENDENCE
    MAUREEN BRONSON; Fiscal Year: 1992
    ....
  27. EFFECTS OF ABUSED DRUGS ON PERCEPTION: AN ANIMAL MODEL
    ROBERT HIENZ; Fiscal Year: 2004
    ..abstract_text> ..
  28. GENDER DIFFERENCES IN THE BRAIN AND BEHAVIOR
    MARLENE WILSON; Fiscal Year: 1999
    ....
  29. BEHAVIORAL EFFECTS OF ABUSED DRUGS
    Roger Spealman; Fiscal Year: 1991
    ..The proposed studies will provide needed quantitative information about the behavioral effects of drugs used persistently in contemporary society...
  30. EFFECTS OF ACUTE BENZODIAZEPINE GROWING WITH TIME
    SEYMOUR ANTELMAN; Fiscal Year: 1990
    ....
  31. Structural Determinants of GABA-A receptor function
    Janet Fisher; Fiscal Year: 2007
    ..The results of this work will help us to understand how variations in the alpha subunit composition of native GABARs can affect the properties of neurons and their responses to GABA. ..
  32. Structure of the GABA-A receptor ligand-binding pocket
    David Wagner; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  33. Neuromodulator Actions in Prefrontal Cortical Neurons
    Zhen Yan; Fiscal Year: 2006
    ..Knowledge gained from this work would contribute to the development of novel therapeutic strategies for many neurological and mental disorders. ..
  34. NOVEL MURINE MODEL RESPONSIVE TO ANXIOLYTICS
    THOMAS SEALE; Fiscal Year: 1993
    ....
  35. Cellular Mechanisms of Antidepressant Action
    Rene Hen; Fiscal Year: 2007
    ..Such a finding would open new therapeutic avenues based on the stimulation of hippocampal neurogenesis, for the treatment of depression-related disorders. ..
  36. REGULATION OF BRAIN SEROTONIN RECEPTORS
    Milt Teitler; Fiscal Year: 1992
    ....
  37. Genetic dissection of anxiety in mice
    Melloni Cook; Fiscal Year: 2005
    ..The results of this R21 application will create a body of data regarding the genetic mechanisms of anxiety upon which future research can be built. ..
  38. Heterotrimeric G alpha subunit activation by typical and atypical GEFs
    Michael Lee; Fiscal Year: 2007
    ..A new class of proteins was recently found to regulate G protein signaling, and here I aim to characterize this class of proteins, in order to create better drugs to treat mood disorders. [unreadable] [unreadable] [unreadable]..
  39. BIOLOGY OF SEROTONIN IN BRAIN
    Irwin Lucki; Fiscal Year: 2006
    ..The results of the proposed work should have important implications for our understanding of synaptic transmission in the brain and of the effect of psychotherapeutic drugs...
  40. Highthroughput analysis of behavior for CNS applications
    Daniela Brunner; Fiscal Year: 2004
    ..Smart Base, with its cumulative normative data in inbred mice will have great impact and value. ..
  41. Potentiation of Neuronal Nicotinic Receptors by Zinc
    Charles Luetje; Fiscal Year: 2007
    ..Changes in open probability will be characterized in terms of the underlying gating mechanism. [unreadable] [unreadable] [unreadable]..
  42. LIMBIC MECHANISMS OF ANXIETY AND STRESS
    Earl Thomas; Fiscal Year: 1999
    ..The acute preparation will combine stimulation and recording to determine the nature of the mutual influence of septum and amygdala. ..
  43. BINDING SITE STRUCTURE OF NEURONAL NICOTINIC RECEPTORS
    Charles Luetje; Fiscal Year: 2002
    ....
  44. Allosteric Coupling in Homomeric Cys-loop Receptors
    STEVEN SINE; Fiscal Year: 2009
    ..Knowledge of how Cys-loop receptors operate at the molecular level is essential to developing therapeutic strategies and drugs with fewer side effects. ..
  45. Impact of Trauma of Terroist Attack on Bipolar Patients
    Mark Pollack; Fiscal Year: 2003
    ..abstract_text> ..
  46. MR SPECTROSCOPIC IMAGING DURING METHADONE MAINTENANCE
    Mark Pollack; Fiscal Year: 2002
    ....
  47. BEHAVIORAL AND PHARMACOLOGICAL TREATMENT FOR INSOMNIA
    Charles Morin; Fiscal Year: 2005
    ....
  48. D-Cycloserine Enhancement of Exposure in Social Phobia
    Mark H Pollack; Fiscal Year: 2010
    ..This study addresses an important public health issue by assessing an intervention that may lead to a more efficient and effective application of empirically based psychosocial interventions for the treatment of SAD. ..
  49. Improving Outcomes in Pharmacotherapy of Social Phobia
    Mark Pollack; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  50. Epidemiology of Prescription Drug Abuse in the United States
    SEAN MCCABE; Fiscal Year: 2007
    ..It will help identify risk factors for substance abuse. Most importantly, the findings will provide guidance for the prevention, assessment, and treatment of prescription drug abuse. [unreadable] [unreadable]..
  51. Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
    Murray Stein; Fiscal Year: 2008
    ..Enhancing the development of new treatments for anxiety is a public health priority. The projects proposed in this application have the potential to achieve this important aim. [unreadable] [unreadable] [unreadable]..
  52. IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE
    Murray Stein; Fiscal Year: 2002
    ..abstract_text> ..
  53. Protective Influence of Residential Learning Communities
    SEAN MCCABE; Fiscal Year: 2006
    ..At each measurement point, participants will complete a set of measures that assess substance use behaviors and constructs addressed by RLCs. ..
  54. Preventing Psychiatric Sequelae of Traumatic Injury
    Murray Stein; Fiscal Year: 2003
    ..Findings will provide justification for and information about optimal parameters (e.g., subject selection; sample size; dose and duration) for a future randomized controlled trial (RCT). ..
  55. Sexual Orientation, Substance Use and Mental Health
    SEAN MCCABE; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  56. TREATMENT REFRACTORY PANIC DISORDER
    Naomi Simon; Fiscal Year: 2004
    ..abstract_text> ..
  57. Nonmedical Prescription Drug Use among College Students
    SEAN MCCABE; Fiscal Year: 2005
    ..Findings from this research will have important implications for the understanding of the epidemiology, prevention and treatment of prescription drug abuse. ..
  58. Improving Outcomes in Pharmacotherapy of Social Phobia
    Murray Stein; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  59. Prescription Drug Abuse Among College Students
    SEAN MCCABE; Fiscal Year: 2005
    ....
  60. Effects of Opioid Pharmacotherapy on Functioning
    MIRIAM MINTZER; Fiscal Year: 2008
    ..Data from this project may also enhance the scientific understanding of pharmacological and cognitive mechanisms. ..